leadership in multiple disease and treatment settings. Many of these first mover opportunities are in gynecologic cancers where there remains significant unmet need. ? The Trofuse 005 study presented at ESMO evaluated SAC TMT in patients with endometrial cancer whose disease has progressed following platinum chemotherapy and anti PD1 L1 immunotherapy, demonstrating a remarkable near seven-month improvement in median overall survival compared to chemotherapy alone. Endometrial cancer is one of the few cancers with increasing incidence and mortality rates worldwide. These patients currently face a very poor prognosis, and we look forward to continuing to work with the FDA to deliver this potential new option as quickly as possible. Second, we are exploring the potential of SAC TMT in certain types of breast and lung cancers where we believe we can be differentiated. In first line, PDL1 negative non squamous non small cell lung cancer results from the optotrope lung O6 study conducted by our partner Keelan showed a meaningful improvement in progression free survival for SAC TMT plus Katruda over Katruda plus chemotherapy, raising the possibility that novel combinations may improve upon the high bar set by Catruda plus chemotherapy. Our global trophuse program includes five ongoing phase three studies in various non-small cell lung cancer settings. We plan to investigate SAC TMT in combination with MK 2010, our PD1 VEGF Bispecific in first line non-small cell lung cancer. Engagement with the FDA has been productive, and we anticipate phase three studies in this setting in the first half of 2027. Now, turning to entismeran. Our deep understanding of tumor biology continues to inform the next generation of our oncology pipeline, including the development of an mRNA therapeutic cancer vaccine based on the unique mutational signature of a patient's tumor. ESMOL marked the unveiling of landmark results for NTSMIRAN, an investigational individualized neoantigen therapy developed in collaboration with Moderna, ? plus Catruda as adjuvant therapy for melanoma. Results of the Interpath 001 study demonstrated clinically meaningful improvements in recurrence-free survival and distant metastases-free survival for antismeran, plus catruda over standard of care katruda in patients with completely resected stage 2B24 melanoma. These results, building on the body of evidence from the phase 2B study, strengthen our confidence in the curative potential of intismeran when given in combination with Catruda. We are actively engaged with the FDA on regulatory submission. Additionally, we are progressing a robust interpath clinical development program across a range of immune-sensitive tumors, including indications in earlier stages of disease where Katruda has established efficacy. Phase three studies are ongoing in melanoma and non-small cell lung cancer, which are characterized by high mutational burden. Ongoing phase two studies are also evaluating tumors with lower mutational burden, including certain platter and renal cancers, to inform potential future expansion. I look forward to sharing further updates on these and other oncology programs. Now to a few regulatory updates. Subcutaneous Pember Elizabeth and Barahyaluranodase Alpha was approved by regulatory authorities in Japan and China. In Europe, we received approval for Catruda plus PATSIV as a perioperative treatment for resectable muscle invasive bladder cancer. And in the US, the FDA approved Wellereg plus Lymvema for the treatment of patients with previously treated renal cell carcinoma. Regarding infinitomab Dirextacan, together with Daiichi Sankiol, we made the decision to withdraw the biologic license application seeking accelerated approval. Multiple studies of IDXD are ongoing in small cell lung cancer, prostate cancer, and other tumor types. Next, in cardiometabolic and respiratory, recently the FDA approved the label update for WinRevere, incorporating results from the phase three Hyperion study, providing further evidence to support its use earlier in the treatment journey for adults with pulmonary arterial hypertension. With WinRivere, we introduced active insignal inhibition, a novel mechanism targeting the underlying vascular remodeling that drives disease progression. Building on the findings from the phase two cadence trial, we are taking an important step to extend the application of active insignaling inhibition beyond group 1 PAH. The upcoming phase 3 core study will evaluate patients with combined post and precapillary pulmonary hypertension associated with heart failure with preserved ejection fraction. This distinct population within Group 2 pulmonary hypertension has similar vascular characteristics to pH and no currently approved treatment options. Next, in immunology. Last month at EADV, positive phase 2B results were presented for Tulusoka BART in patients with hydranitis superativa, making it the first anti-TO1A antibody to demonstrate positive clinical data in a dermatology indication. The study demonstrated promising clinical responses and encouraging safety profile. Based on these findings, we plan to advance Tulasocobart into phase three development in HS. Finally, to ophthalmology, as Rob mentioned, earlier this month, results were presented from the Phase 2B 3 Brunello study, the first of two pivotal studies evaluating RemigramIG, a novel WIMP agonist in adults with DME. Brunello achieved its primary endpoint with both doses of monthly Remigramig, demonstrating non inferior best corrected visual acuity compared to monthly 0.5 milligram rhanobismab at one year. While anti VEGF therapies have transformed the treatment of DME, disease activity persists in many patients, highlighting the need for new therapeutic options. Brunello provides clinical evidence that activation of the wind pathway can achieve non inferior efficacy to an anti VEGEF agent in DME. If confirmed in the companion Barolo trial, Remig Ramig could introduce a promising new and orthogonal mechanism and help advance the field of ophthalmology toward therapeutic strategies involving multiple pathways. In closing, the breadth of these milestones reflects our progress in translating novel advances in the understanding of disease biology into potentially significant medicines across diverse therapeutic areas. Over the next 12 months, we anticipate several important clinical and regulatory milestones, including in immunology for Tulus Oker, we are compiling data from the Phase III Atlas UC study and expect to share the results in the near term. In ophthalmology, the readout of the Barolo study of Remigramig. In cardiometabolic and respiratory, the initiation of the phase three core study. In infectious disease, anticipated regulatory filings for Islochavir plus Lenicapavir, the potential first once-weekly Oral II drug treatment regimen for HIV, data from the phase three anchor study evaluating MK 1406, our investigational long-acting and strain agnostic antiviral designed to prevent influenza, and the data from the phase three expressive program of our investigational once monthly oral HIV prep option, Alomatrovair. And finally, in oncology, the potential approval of FACTMT in endometrial cancer and additional phase three readouts, the anticipated regulatory filing of anticiparan, and additional readouts in multiple other programs. And now I will turn the call back to Peter.
Passages & reports (30) 16:35 leadership in multiple disease and treatment settings. Many of these first mover opportuni… Report 16:46 The Report 16:46 Trofuse 005 study presented at ESMO evaluated SAC TMT in patients with endometrial cancer … Report 17:06 survival compared to chemotherapy alone. Endometrial cancer is one of the few cancers with… Report 17:26 quickly as possible. Second, we are exploring the potential of SAC TMT in certain types of… Report 17:46 our partner Keelan showed a meaningful improvement in progression free survival for SAC TM… Report 18:06 ongoing phase three studies in various non-small cell lung cancer settings. We plan to inv… Report 18:26 studies in this setting in the first half of 2027. Now, turning to entismeran. Our deep un… Report 18:46 a patient's tumor. ESMOL marked the unveiling of landmark results for NTSMIRAN, an investi… Report 18:58 plus Report 18:58 Catruda as adjuvant therapy for melanoma. Results of the Interpath 001 study demonstrated … Report 19:18 completely resected stage 2B24 melanoma. These results, building on the body of evidence f… Report 19:37 regulatory submission. Additionally, we are progressing a robust interpath clinical develo… Report 19:57 non-small cell lung cancer, which are characterized by high mutational burden. Ongoing pha… Report 20:17 oncology programs. Now to a few regulatory updates. Subcutaneous Pember Elizabeth and Bara… Report 20:37 invasive bladder cancer. And in the US, the FDA approved Wellereg plus Lymvema for the tre… Report 20:56 approval. Multiple studies of IDXD are ongoing in small cell lung cancer, prostate cancer,… Report 21:16 evidence to support its use earlier in the treatment journey for adults with pulmonary art… Report 21:36 trial, we are taking an important step to extend the application of active insignaling inh… Report 21:56 fraction. This distinct population within Group 2 pulmonary hypertension has similar vascu… Report 22:16 Tulusoka BART in patients with hydranitis superativa, making it the first anti-TO1A antibo… Report 22:36 phase three development in HS. Finally, to ophthalmology, as Rob mentioned, earlier this m… Report 22:56 achieved its primary endpoint with both doses of monthly Remigramig, demonstrating non inf… Report 23:15 highlighting the need for new therapeutic options. Brunello provides clinical evidence tha… Report 23:35 orthogonal mechanism and help advance the field of ophthalmology toward therapeutic strate… Report 23:55 medicines across diverse therapeutic areas. Over the next 12 months, we anticipate several… Report 24:15 term. In ophthalmology, the readout of the Barolo study of Remigramig. In cardiometabolic … Report 24:35 regimen for HIV, data from the phase three anchor study evaluating MK 1406, our investigat… Report 24:54 Alomatrovair. And finally, in oncology, the potential approval of FACTMT in endometrial ca… Report 25:14 call back to Peter. Report